Milada Zemanová

5.5k total citations · 1 hit paper
66 papers, 1.3k citations indexed

About

Milada Zemanová is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Milada Zemanová has authored 66 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in Milada Zemanová's work include Lung Cancer Treatments and Mutations (18 papers), Renal cell carcinoma treatment (16 papers) and Lung Cancer Research Studies (14 papers). Milada Zemanová is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Renal cell carcinoma treatment (16 papers) and Lung Cancer Research Studies (14 papers). Milada Zemanová collaborates with scholars based in Czechia, United States and Poland. Milada Zemanová's co-authors include Luboš Petruželka, Libor Havel, Petr Zatloukal, Dalibor Kodrı́k, Ladislav Pecen, Libor Judas, Filip Jankú, E Kr̆epela, A Kubík and Pavel Fiala and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Milada Zemanová

61 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2

2024 37 citations Milada Zemanová et al. profile →

Peers

Countries citing papers authored by Milada Zemanová

Since Specialization

Citations

This map shows the geographic impact of Milada Zemanová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Milada Zemanová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Milada Zemanová more than expected).

Fields of papers citing papers by Milada Zemanová

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Milada Zemanová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Milada Zemanová. The network helps show where Milada Zemanová may publish in the future.

Co-authorship network of co-authors of Milada Zemanová

This figure shows the co-authorship network connecting the top 25 collaborators of Milada Zemanová. A scholar is included among the top collaborators of Milada Zemanová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Milada Zemanová. Milada Zemanová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	297MO: Patterns of disease progression with durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Results from ADRIATIC 2025 ·Journal of Thoracic Oncology ·Suresh Senan, Ying Cheng, (unknown), Byoung Chul Cho, (unknown), (unknown), Ki Hyeong Lee, (unknown), Isamu Okamoto, Sema Sezgin Göksu, A. Badzio, Aiping Shi, Milada Zemanová, (unknown), P. Iyengar, (unknown), Jie Chen, (unknown), (unknown), Yuanbin Chen	0
2	LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial 2024 ·Annals of Oncology ·(unknown), David R. Spigel, Byoung Chul Cho, К. К. Лактионов, Yoshitaka Zenke, Ki Hyeong Lee, (unknown), (unknown), (unknown), Sema Sezgin Göksu, A. Badzio, (unknown), Davey B. Daniel, Milada Zemanová, P. Iyengar, Luis Paz‐Ares, Leah Szadkowski, (unknown), (unknown), (unknown)	4
3	Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment 2021 ·Anticancer Research ·(unknown), (unknown), Jana Krejčí, Milada Zemanová, (unknown), Juraj Kultan, (unknown), Jana Skřičková, (unknown), Markéta Černovská, (unknown), (unknown), (unknown), (unknown), Leona Koubková, (unknown), (unknown), Miloš Pešek, Martin Svatoň	0
4	Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment 2021 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), Monika Tomaszewska‐Kiecana, Rodryg Ramlau, (unknown), Yvette Drew, Rafał Dziadziuszko, Milada Zemanová, (unknown), (unknown), (unknown), Mingxiang Liao, Jim Xiao	11
5	Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors 2021 ·In Vivo ·Jindřich Kopecký, Ondřej Kubeček, Tomáš Büchler, Bohuslav Melichar, Alexandr Poprach, Milada Zemanová, (unknown), Igor Kišš, Jaroslav Hájek, Hana Študentová, (unknown)	1
6	Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry 2020 ·Thoracic Cancer ·Kristián Brat, (unknown), Jana Skřičková, (unknown), (unknown), Miloš Pešek, Libor Havel, Leona Koubková, (unknown), Jana Krejčí, (unknown), Milada Zemanová, (unknown), Martin Svatoň	7
7	Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe 2020 ·Radiology and Oncology ·Milada Zemanová, Marko Jakopović, (unknown), (unknown), Martina Vrankar, (unknown), Tudor–Eliade Ciuleanu, Davorin Radosavljević, Krisztina Bogos, Sergiusz Nawrocki	2
8	Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer 2020 ·Anticancer Research ·Martin Svatoň, Milada Zemanová, (unknown), Juraj Kultan, (unknown), Jana Skřičková, (unknown), Markéta Černovská, (unknown), (unknown), (unknown), (unknown), (unknown), Jiří Blažek, (unknown), (unknown), Bohuslav Melichar	68
9	Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database 2019 ·Urologic Oncology Seminars and Original Investigations ·Alexandr Poprach, (unknown), Radek Lakomý, (unknown), Michal Staník, (unknown), Igor Kišš, Ondřej Slabý, Hana Študentová, Bohuslav Melichar, Jaroslav Juráček, Ondřej Fiala, Jindřich Kopecký, Kateřina Kopečková, Milada Zemanová, Tomáš Büchler	5
10	Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients 2018 ·Anticancer Research ·Alexandr Poprach, Ondřej Fiala, (unknown), Bohuslav Melichar, Radek Lakomý, Katarína Petráková, Milada Zemanová, Kateřina Kopečková, Ondřej Slabý, Hana Študentová, Jindřich Kopecký, Igor Kišš, Jindřich Fínek, Ladislav Dušek, Tomáš Büchler	5
11	Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer 2017 ·Clinical Genitourinary Cancer ·Tomáš Büchler, Alexandr Poprach, Zbyněk Bortlíček, Radek Lakomý, (unknown), Rostislav Vyzula, Milada Zemanová, Kateřina Kopečková, Marek Svoboda, Ondřej Slabý, Igor Kišš, Hana Študentová, (unknown), Ondřej Fiala, Jindřich Kopecký, Jindřich Fínek, Ladislav Dušek, Bohuslav Melichar	8
12	Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry 2017 ·BMC Cancer ·Radek Lakomý, Alexandr Poprach, Zbyněk Bortlíček, Bohuslav Melichar, (unknown), Rostislav Vyzula, Milada Zemanová, Kateřina Kopečková, Marek Svoboda, Ondřej Slabý, Igor Kišš, Hana Študentová, Jaroslav Juráček, Ondřej Fiala, Jindřich Kopecký, Jindřich Fínek, Ladislav Dušek, Karel Hejduk, Tomáš Büchler	9
13	Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics? 2017 ·PubMed Central ·(unknown), (unknown), (unknown), Milada Zemanová, Katarína Kološtová, Vladimír Bobek	13
14	Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice 2016 ·Drugs & Aging ·(unknown), Alexandr Poprach, Radek Lakomý, Zbyněk Bortlíček, Bohuslav Melichar, Tomáš Pavlík, Ondřej Slabý, Rostislav Vyzula, Marek Svoboda, Igor Kišš, Hana Študentová, Milada Zemanová, Ondřej Fiala, Kateřina Kubáčková, Ladislav Dušek, (unknown), Tomáš Büchler	15
15	FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal–gastric junction 2016 ·Abdominal Radiology ·(unknown), Otakar Bělohlávek, Tomáš Haruštiak, Milada Zemanová	5
16	Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency 2015 ·European Journal of Cancer ·Alexandr Poprach, Zbyněk Bortlíček, Bohuslav Melichar, Radek Lakomý, Marek Svoboda, Igor Kišš, Milada Zemanová, Ondřej Fiala, Kateřina Kubáčková, Oldřich Coufal, Tomáš Pavlík, Ladislav Dušek, Rostislav Vyzula, Tomáš Büchler	10
17	Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis 2014 ·Urologic Oncology Seminars and Original Investigations ·Tomáš Büchler, Zbyněk Bortlíček, Alexandr Poprach, Kateřina Kubáčková, Igor Kišš, Milada Zemanová, Ondřej Fiala, Ladislav Dušek, Rostislav Vyzula, Bohuslav Melichar	12
18	Peri-operative Chemotherapy in Patients with Oesophageal and Gastro-oesophageal Junction Cancer – Three Years of Experience 2013 ·Prague Medical Report ·(unknown), Milada Zemanová, Tomáš Haruštiak, Pavel Vítek, (unknown)	2
19	Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial 2003 ·Lung Cancer ·Petr Zatloukal, Luboš Petruželka, Milada Zemanová, Vı́tězslav Kolek, Jana Skřičková, Miloš Pešek, (unknown), Martin Roubec, Libor Havel, Petr Průša	41
20	Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial 2003 ·Lung Cancer ·Petr Zatloukal, Luboš Petruželka, Milada Zemanová, Vı́tězslav Kolek, Jana Skřičková, Miloš Pešek, (unknown), (unknown), (unknown), Jaromı́r Roubec, (unknown), Libor Havel, Petr Průša, (unknown), Tomáš Skácel, M Kůta	139

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact